# A Real-World Safety Profile in Neurological, Skin, and Sexual Disorders of Anti-Seizure Medications Using the Pharmacovigilance Database of the Korea Adverse Event Reporting System (KAERS)

**Authors:** Dajeong Kim, Sukhyang Lee

PMC · DOI: 10.3390/jcm13133983 · 2024-07-08

## TL;DR

This study analyzes real-world safety data of anti-seizure medications in Korea, revealing distinct adverse reaction patterns between two drug types.

## Contribution

The study provides novel real-world safety evidence for anti-seizure medications using Korea's pharmacovigilance database.

## Key findings

- SCBs caused more skin and neurological disorders compared to non-SCBs.
- Sexual/reproductive disorders were rare but more commonly linked to SCBs.
- Rash and pruritus occurred later with SCBs than non-SCBs.

## Abstract

(1) Background: The utilization of high-quality evidence regarding the safety of anti-seizure medications (ASMs) is constrained by the absence of standardized reporting. This study aims to examine the safety profile of ASMs using real-world data. (2) Methods: The data were collected from the Korea Adverse Event Reporting System Database (KAERS-DB) between 2012 and 2021. In total, 46,963 adverse drug reaction (ADR)–drug pairs were analyzed. (3) Results: At the system organ class level, the most frequently reported classes for sodium channel blockers (SCBs) were skin (37.9%), neurological (16.7%), and psychiatric disorders (9.7%). For non-SCBs, these were neurological (31.2%), gastrointestinal (22.0%), and psychiatric disorders (18.2%). The most common ADRs induced by SCBs were rash (17.8%), pruritus (8.2%), and dizziness (6.7%). Non-SCBs were associated with dizziness (23.7%), somnolence (13.0%), and nausea (6.3%). Rash, pruritus, and urticaria occurred, on average, two days later with SCBs compared to non-SCBs. Sexual/reproductive disorders were reported at a frequency of 0.23%. SCBs were reported as the cause more frequently than non-SCBs (59.8% vs. 40.2%, Fisher’s exact test, p < 0.0001). (4) Conclusions: Based on real-world data, the safety profiles of ASMs were identified. The ADRs induced by SCBs exhibited different patterns when compared to those induced by non-SCBs.

## Full-text entities

- **Diseases:** psychiatric disorders (MESH:D001523), urticaria (MESH:D014581), Sexual/reproductive disorders (MESH:D060737), nausea (MESH:D009325), dizziness (MESH:D004244), Neurological, Skin, and Sexual Disorders (MESH:D009461), Rash (MESH:D005076), pruritus (MESH:D011537), ADR (MESH:D064420), somnolence (MESH:D006970), gastrointestinal (MESH:D005767)
- **Chemicals:** Anti-Seizure Medications (-)

---
Source: https://tomesphere.com/paper/PMC11242241